0001493152-21-021927.txt : 20210903 0001493152-21-021927.hdr.sgml : 20210903 20210903070046 ACCESSION NUMBER: 0001493152-21-021927 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210831 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210903 DATE AS OF CHANGE: 20210903 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncotelic Therapeutics, Inc. CENTRAL INDEX KEY: 0000908259 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133679168 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21990 FILM NUMBER: 211235124 BUSINESS ADDRESS: STREET 1: 29397 AGOURA RD. STREET 2: #107 CITY: AGUORA HILLS STATE: CA ZIP: 91301 BUSINESS PHONE: 650-635-7000 MAIL ADDRESS: STREET 1: 29397 AGOURA RD. STREET 2: #107 CITY: AGUORA HILLS STATE: CA ZIP: 91301 FORMER COMPANY: FORMER CONFORMED NAME: MATEON THERAPEUTICS INC DATE OF NAME CHANGE: 20160613 FORMER COMPANY: FORMER CONFORMED NAME: OXIGENE INC DATE OF NAME CHANGE: 19930628 8-K 1 form8-k.htm
0000908259 false 0000908259 2021-08-31 2021-08-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

August 31, 2021

 

 

 

ONCOTELIC THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-21990   13-3679168

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

29397 Agoura Road, Suite 107

Agoura Hills, CA 91301

(Address of principal executive offices and Zip Code)

 

Registrant’s telephone number, including area code

(650) 635-7000

 

Not applicable.

(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of class   Trading Symbols   Name of each exchange on which registered
N/A   OTLC    

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On August 31, 2021, Oncotelic Therapeutics, Inc. (the “Company”) entered into a binding term sheet (“Term Sheet”) with Autotelic, Inc. (“Autotelic”) whereby the Company will license AL-101, intranasal apomorphine, from Autotelic (the “License”). Pursuant to the Term Sheet, the Company will make payments to Autotelic, upon the achievement of certain financial and regulatory milestones in the development of AL-101, as shown below. The Term Sheet does not contemplate any upfront payment and all payments are planned to be made upon the achievement of the milestones. In addition, the payments of the milestones are for 3 indications of AL-101, namely erectile dysfunction (“ED”), Parkinson’s Disease (“PD”) and female sexual dysfunction (“FSD”).

 

Milestones   Transaction Value     Actions
           
Tranche 1   $ 1,000,000     Upon the earlier to occur of: (i) the Company receiving an investment of at least $20 million, and (ii) the uplisting of the Company’s common stock to any NASDAQ market or the New York Stock Exchange.
             
Tranche 2   $ 2,000,000     Upon approval by the United States Food and Drug Administration of the Company’s 505(b)2 application for purposes of treating PD.
             
Tranche 3   $ 2,000,000     Upon first patient in (“FPI”) for any clinical trial supporting the use of AL-101 for the treatment of PD or ED.
             
Tranche 4   $ 2,500,000     Upon FPI for phase 2 clinical trials supporting the use of AL-101 to treat FSD.
             
Tranche 5   $ 2,500,000     Upon FPI for phase 3 clinical trials supporting the use of AL-101 to treat FSD
             
Tranche 6   $ 10,000,000     Upon Marketing approval for the use of AL-101 to treat PD.
             
Tranche 7   $ 10,000,000     Upon Marketing approval for the use of AL-101 to treat ED.
             
Tranche 8   $ 10,000,000     Upon Marketing approval for the use of AL-101 to treat FSD
             
Tranche 9   $ 10,000,000     Upon the earlier of: (i) the Company entering into a licensing agreement with a third party for the use of AL-101 for the treatment of PD, ED or FSD with an aggregate licensing value of at least $50 million; and (ii) the Company’s gross revenue derived from sales of AL-101 for the treatment of PD, ED or FSD reaches at least $50.0 million.

 

-2-
 

 

The Company will also pay royalties to Autotelic, equal to an amount yet to be agreed upon, but such amount to be not less than 15% of the Company’s net sales of AL-101 once developed.

 

The Term Sheet is subject to certain conditions including, without limitation, the negotiation and approval of definitive documentation regarding the License (the “Definitive Agreement”), the Board of Directors of the Company approving the Definitive Agreement, completion of due diligence, and receipt of any necessary governmental approvals, if required. The Term Sheet is subject to termination within 30 days of execution, unless extended by mutual agreement of the Company and Autotelic.

 

The Company’s Chief Executive Officer, Mr. Vuong Trieu, is the majority owner of Autotelic.

 

The foregoing summary of the terms of the Term Sheet do not purport to be complete and is qualified in its entirety by reference to the Term Sheet, a copy of which is filed as Exhibit 10.1 to this Report and is incorporated herein by reference.

 

Item 7.01 Regulation FD Disclosure.

 

On September 1, 2021, the Company issued a press release announcing the entry into the Term Sheet with Autotelic. A copy of the press release is attached hereto as Exhibit 99.1.

 

Disclaimer.

 

The information in Section 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description   Incorporation by reference
         
10.1   Term Sheet between Oncotelic Therapeutics, Inc. and Autotelic, Inc., dated August 31, 2021   Filed herewith.
99.1   Press Release dated September 1, 2021   Filed herewith
         
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)    

 

-3-
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Oncotelic Therapeutics, Inc.
     
Date: September 3, 2021   /s/ Vuong Trieu
  By: Vuong Trieu
    Chief Executive Officer

 

-4-

 

 

 

 EX-10.1 2 ex10-1.htm

 

Exhibit 10.1

 

Oncotelic Therapeutics, Inc.

29397 Agoura Rd., Suite 107 Agoura Hills, CA 91301

 

STRICTLY CONFIDENTIAL

 

Oncotelic Therapeutics, Inc (Oncotelic) and Autotelic Inc. (Autotelic) Term Sheet

 

The following term sheet (“Term Sheet”) sets forth a summary of the basic terms of a contemplated licensing transaction (“Transaction”), wherein Oncotelic, a Delaware Corporation with its shares traded on OTCQB (OTLC) and Autotelic, a California Corporation, would enter into a licensing transaction, with an anticipated closing date no later than the 4th quarter of 2021. This Term Sheet is binding on the parties and shall survive termination as defined.

 

Consideration Autotelic will out-license its product comprising of the intra-nasal drug and delivery system related to, but not limited to, nasal apomorphine (the “Product”) to Oncotelic. Oncotelic shall in-license the Product for the indications and for the consideration as shown in Schedule A below.  
   
Structure Subject to U.S. tax laws and other considerations, the Transaction will be structured as a standard licensing transaction.
   
Conditions to Closing Principal conditions to the consummation of the Transaction will include, among others:
     
  1. Completion of a due diligence review to the satisfaction of both parties
  2. No material adverse change at Autotelic or Oncotelic.
  3. Approval of the licensing transaction by the respective Board of Directors of Oncotelic and of Autotelic prior to signature of the Definitive Agreement(s).
  4. Receipt of all necessary approvals, including governmental consents, if any.
     
Covenants Each party shall continue to maintain and operate its business in the ordinary course prior to closing.
   
Publicity By joint approvals from both parties.
   
Execution and exclusivity The parties agree to not take more than five (5) days for the execution of this Term Sheet and 30 days from signing the term sheet to enter into a definitive agreement.

 

 
ONCOTELIC / OTLC Term Sheet -- Strictly Confidential

 

Intellectual Property Autotelic owns, or has the right to use under license, all Intellectual Property Rights necessary for the operation of its business as conducted prior to the execution of the Term Sheet.
   
Representations Warranties Absence of Litigation by either Party.
   
Confidentiality The Parties signed a mutual non-disclosure agreement on August 12, 2021.
   
Termination This Term Sheet will terminate if and when (a) the Definitive Agreement(s) are signed (b) mutual agreement of the parties to terminate any further discussions or (b) the date that is 30 calendar days after the date of this Term Sheet unless the parties mutually agree to extend.
   
Governing Law California, without regard to conflict of laws principles.

 

[Remainder of Page Intentionally Left Blank; Next Page is Signature Page]

 

-2-
ONCOTELIC / OTLC Term Sheet -- Strictly Confidential

 

[SIGNATURE PAGE TO TERM SHEET]

 

Autotelic Inc.   Oncotelic Therapeutics, Inc.
         
By: /s/ Chulho Park   By: /s/ Saran Saund
Name: Chulho Park PhD     Name: Saran Saund   
Title: Chief Scientific Officer   Title: Chief Business Officer
Date: 08/31/2021      Date: 08/31/2021  

 

-3-
ONCOTELIC / OTLC Term Sheet -- Strictly Confidential

 

EXHIBIT A

 

Schedule of Oncotelic Payments by Milestone to Autotelic

 

Milestones  Transaction Value   Actions
        
Tranche 1  $1,000,000   Upon fund raising of $20M or more by Oncotelic or uplisting to Nasdaq/NYSE.  
         
Tranche 2  $2,000,000   Upon FDA acceptance of 505(b)2 pathway for Parkinson’s Disease (PD)
         
Tranche 3  $2,000,000   Upon first patient in (FPI) for any clinical trial supporting PD or erectile dysfunction (ED)
         
Tranche 4  $2,500,000   Upon first patient in (FPI) for phase 2 clinical trial supporting female sexual dysfunction (FSD)
         
Tranche 5  $2,500,000   Upon first patient in (FPI) for phase 3 clinical trial supporting FSD
         
Tranche 6  $10,000,000   Upon Marketing approval for PD
         
Tranche 7  $10,000,000   Upon Marketing approval for ED
         
Tranche 8  $10,000,000   Upon Marketing approval for FSD
         
Tranche 9  $10,000,000   When either or all of the assets for PD, ED or FSD achieves licensing deal of value of $50M or over OR when either or all of the assets for PD, ED or FSD achieves gross revenues of $50M or over.

 

In Addition, Royalties on net sales at a rate to be defined in the Definitive Agreement(s) but not less than 15%.

 

-4-
ONCOTELIC / OTLC Term Sheet -- Strictly Confidential

 

EXHIBIT B

 

Intellectual Property Listing

 

-5-

 

 

 EX-99.1 3 ex99-1.htm

 

Exhibit 99.1

 

 

Oncotelic to Acquire LATE-STAGE drug candidate for Parkinson Disease, Erectile Dysfunction, and Female Sexual Dysfunction.

 

AGOURA HILLS, Calif., September 1, 2021 - Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), executed a binding term sheet with Autotelic Inc. to license AL-101 (intranasal apomorphine). Oncotelic intends to develop AL-101 via fast-to-market 505(b)2 regulatory pathway for Parkinson Disease (“PD”) and Erectile Dysfunction (“ED”), especially phosphodiesterase 5 (“PDE5”) non-responders. AL-101 will also be developed as a new drug against Female Sexual Dysfunction (“FSD”), including Hypoactive Sexual Desire Disorder (“HSDD”). AL-101 has a favorable safety and efficacy profile and is phase 3 ready with six clinical trials completed and over 200 patients (2,200 doses) treated.

 

“The acquisition of AL-101, expands Oncotelic’s product portfolio to the fast to market 505(b)2 regulatory pathway. AL-101 has many of the same properties necessary to replicate the successes I had with the 505(b)2 route for Abraxane at Abraxis and Cynviloq at Igdrasol. I am impressed with its marked improvement on quality of life for PD patients and look forward to working with pts and healthcare professionals in PD.” said Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

 

About Parkinson Disease (PD):

 

Over 60,000 new patients being diagnosed with PD in the United States and currently there are over 1 million patients in the US and expected to increase to over 1.2 million by 2030. In addition, approximately 10 million suffer from this disease globally. https://www.parkinson.org/Understanding-Parkinsons/Statistics.

 

On May 2020, KYNMOBI™ (apomorphine HCI) sublingual film developed by Sunovion Pharmaceuticals was approved through the 505(b)2 pathway for acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD) dissolves under the tongue. Per Suniovion Pharmaceuticals, Kynmobi is expected to generate $219 million annually. https://www.pharmaceutical-technology.com/comment/sunovion-pharmaceuticals-kynmobi-parkinsons/

 

About Erectile Dysfunction (ED)

 

ED is the most prevalent male sexual disorder globally. The market will continue to grow due to increased vascular disorders followed by the aging population across the world. Furthermore, rising psychological problems, followed by chronic diseases like diabetes, alcohol, and smoking habits are also considered as one of the major driving factors for the growth of the market. Oral PDE5 inhibitors, especially Viagra, Cialis, and Levitra, dominated the market with around US$3.8 billion of revenue in 2020.

 

 

 

 

The percentages of men affected by ED are as follows: 14.3-70% of men aged ≥60 years, 6.7-48% of men aged ≥70 years, and 38% of men aged ≥80 years (Geerkens MJM et al. (2019). Eur Urol Focus. pii: S2405-4569(19)30079-3). However, with the increasing administration of PDE5 inhibitors in clinical practice, it was found that approximately 30-35% of ED patients are treatment failures (McMahon CN et al. (2006). BMJ, 332: 589-92). AL-101 is designed to target treatment failure ED patients who do not respond to PDE5 inhibitors.

 

About Female Sexual Dysfunction (FSD):

 

Female sexual dysfunction is a prevalent problem, afflicting approximately 40% of women and there are few treatment options. FSD is more typical as women age and is a progressive and widespread condition. (Allahdadi, KJ et al. (2009) Cardiovascular & hematological agents in medicinal chemistry, 7(4), 260–269).

 

HSDD is characterized by a low sexual desire, that causes marked distress or interpersonal difficulty, and is not due to a co-existing medical or psychiatric condition, problems within the relationship or the effects of a medication or other drug substance. HSDD affects approximately 5.8 million U.S. premenopausal women (1 in 10 premenopausal women). Almost 98%, approximately 5.7 million of affected premenopausal women are not on any therapy for HSDD, either due to lack of education or lack of therapies available. One in 10 premenopausal women have low desire with associated distress.

 

There is no available drug for the treatment of FSD. In June 2019, the U.S. Food and Drug Administration approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. This is the only available drug treatment. Vyleesi has essentially replaced the only other drug for HSDD - however, it has a long list of drug-drug interactions, including commonly used antidepressants, such as fluoxetine and sertraline. In addition, it has a black box warning regarding its use with alcohol, a combination that has been associated with hypotension and syncopal episodes. Therefore there is an urgent need for effective therapy against FSD and HSDD.

 

About Oncotelic Therapeutics

 

Oncotelic Therapeutics, Inc. (f/k/a Mateon Therapeutics, Inc.) (“Oncotelic”), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020.

 

Oncotelic was created by the 2019 merger with Oncotelic Inc., which became a wholly owned subsidiary of Mateon, thereby creating an immuno-oncology company dedicated to the development of first in class RNA therapeutics, as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-β RNA therapeutic that exhibited single agent activity in some relapsed/refractory cancer patients in clinical trial settings. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic also has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi 4503). The Company acquired PointR Data Inc. (“PointR”) in November 2019. The PointR Acquisition was intended to create a publicly traded artificial intelligence driven immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late-stage cancers such as gliomas, pancreatic cancer and melanoma.

 

For more information, please visit www.oncotelic.com.

 

 

 

 

Oncotelic’s Cautionary Note on Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “promising”, “will”, “conviction”, “estimate,” “intend,” “believe”, “quest for a cure of cancer”, “innovation-driven”, “paradigm-shift”, “high scientific merit”, “impact potential” and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans, the progress, timing, clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various cancer indications. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company’s annual report on Form 10-K filed with the SEC on May 20, 2020 and in the company’s other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information future events, or otherwise.

 

Contact Information:

 

For Oncotelic Therapeutics, Inc.:

Amit Shah

ashah@oncotelic.com

 

 

 

 GRAPHIC 4 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 5 otlc-20210831.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 otlc-20210831_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 otlc-20210831_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000908259 2021-08-31 2021-08-31 iso4217:USD shares iso4217:USD shares 0000908259 false 8-K 2021-08-31 ONCOTELIC THERAPEUTICS, INC. DE 000-21990 13-3679168 29397 Agoura Road Suite 107 Agoura Hills CA 91301 (650) 635-7000 false false false false false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Aug. 31, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 31, 2021
Entity File Number 000-21990
Entity Registrant Name ONCOTELIC THERAPEUTICS, INC.
Entity Central Index Key 0000908259
Entity Tax Identification Number 13-3679168
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 29397 Agoura Road
Entity Address, Address Line Two Suite 107
Entity Address, City or Town Agoura Hills
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91301
City Area Code (650)
Local Phone Number 635-7000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://oncotelic.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex10-1.htm ex99-1.htm otlc-20210831.xsd otlc-20210831_lab.xml otlc-20210831_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "otlc-20210831_lab.xml" ] }, "presentationLink": { "local": [ "otlc-20210831_pre.xml" ] }, "schema": { "local": [ "otlc-20210831.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "OTLC", "nsuri": "http://oncotelic.com/20210831", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-08-31to2021-08-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://oncotelic.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-08-31to2021-08-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 16 0001493152-21-021927-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-021927-xbrl.zip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�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end